Materias dentro de su búsqueda.
Mostrando 161 - 169 Resultados de 169 Para Buscar '"M.Sc."', tiempo de consulta: 0.65s Limitar resultados
  1. 161
    “….: Stocks/Bonds Daniel Curcio, M.Sc., Pfizer Inc.: Employee|Pfizer Inc.: Stocks/Bonds Elizabeth Begier, M.D., M.P.H., Pfizer: Employee|Pfizer: Stocks/Bonds Mark Rozenbaum, Ph.D., M.B.A., Pfizer Inc.: Employee|Pfizer Inc.: Stocks/Bonds.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2207. Rates of Lower Respiratory Tract Infections Among US Adults Aged ≥18 Years With and Without Chronic Medical Conditions
  2. 162
    “…DISCLOSURES: Michelle J. Alfa, B.Sc., M.Sc., Ph.D, Healthmark (Consultant, Other Financial or Material Support, Royalty monies from University of Manitoba that are provided through a License agreement with Healthmark)Kikkoman (Consultant)Olympus (Consultant, Advisor or Review Panel member, Speaker’s Bureau)STERIS (Consultant, Speaker’s Bureau)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    815. Biofilm Accumulation in New Flexible Gastroscope Channels within 30 Days in Clinical Use
  3. 163
    “…Margolis, MD MPH, Brii Biosciences: Stocks/Bonds Ji Ma, PhD, Brii Biosciences: Stocks/Bonds Michael Watkins, PharmD, Brii Biosciences: Stocks/Bonds Yujin Wang, M.Sc., Brii Biosciences: Stocks/Bonds Chetana Trivedi, B.A., Brii Biosciences: Stocks/Bonds Xuelian Wei, PhD, Brii Biosciences: Stocks/Bonds Lijie Zhong, PhD, Brii Biosciences: Stocks/Bonds Kamlesh Patel, PhD, Brii Biosciences: Stocks/Bonds Li Yan, MD PhD, Brii Biosciences: Stocks/Bonds Zhi Hong, PhD, Brii Biosciences: Ownership Interest Jean-Luc Girardet, PhD, Brii Biosciences: Stocks/Bonds Lianhong Xu, PhD, Brii Biosciences: Stocks/Bonds.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1283. Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects
  4. 164
    por Dedecker, Ruben
    Publicado 2023
    “…</span></p><p class="MsoNormal"><span style="color:hsl(0,0%,0%);"><span style="font-family:&quot;Calibri&quot;,sans-serif;font-size:11.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;;"><strong>Lecturer's Bio:</strong></span></span></p><p class="MsoNormal"><span style="font-family:&quot;Calibri&quot;,sans-serif;font-size:11.0pt;mso-fareast-font-family:&quot;Times New Roman&quot;;">Ruben Dedecker received a M.Sc. degree in Computer Science (2020) from Ghent University (Belgium). …”
    Enlace del recurso
    2nd Series on Data Protection - Control your data on the Web: An introduction to Solid and Linked Data
  5. 165
    “…McCoig, MD, ViiV Healthcare (Employee) Joseph Polli, PhD, FAAPS, ViiV Healthcare (Employee) David Margolis, MD, MPH, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee) Rodica Van Solingen-Ristea, MD, Janssen R&D (Employee) Kati Vandermeulen, M.SC., Janssen Pharmaceutica (Employee, Shareholder) William Spreen, PharmD, ViiV Healthcare (Employee, Shareholder) Parul Patel, PharmD, ViiV Healthcare (Employee)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies
  6. 166
    “…Upadhyay, MPH, MBA, GlaxoSmithKline (Employee) Louise Garside, PhD, GlaxoSmithKline (Employee) Rodica Van Solingen-Ristea, MD, Janssen Research and Development (Employee)ViiV Healthcare (Employee) Kati Vandermeulen, M.SC., Janssen Research and Development (Employee) William Spreen, PharmD, GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results
  7. 167
    “…Andrew, MD, PhD, GSK (Grant/Research Support)Pfizer (Grant/Research Support, Advisor or Review Panel member)Sanofi (Consultant, Grant/Research Support, Advisor or Review Panel member)Seqirus (Advisor or Review Panel member) Allison McGeer, MSc,MD,FRCPC,FSHEA, GlaxoSmithKline (Advisor or Review Panel member)Merck (Advisor or Review Panel member, Research Grant or Support)Pfizer (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member) Louis Valiquette, MD, M.Sc., Cubist (Consultant)GSK (Grant/Research Support)Merck (Consultant)Optimer (Consultant)Pfizer (Grant/Research Support) Shelly McNeil, FRCPC, MD, GSK (Grant/Research Support)Pfizer (Grant/Research Support)Sinofi Pasteur (Grant/Research Support)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1325. Recalibrating Estimates of Pneumococcal Disease in Hospitalized Canadian adults from 2010 to 2017 with Use of an Extended Spectrum Serotype-specific Urine Antigen Detection
  8. 168
    “…Thus, the application of ultrasound in the diagnosis of vascular disease is an exciting medical innovation. 14 June 2002 Magnetic Resonance Pr. Roland Kreis, M.Sc., PhD, University Hospital Bern Magnetic Resonance in Medicine: Morphology and Way Beyond Nuclear magnetic resonance is a phenomenon with extremely wide-varying applications ranging from solid-state physics to conformation analysis of macromolecules, to a plethora of uses in medicine. …”
    Enlace del recurso
    Physics technologies in medicine
  9. 169
    “…After informed consent patients are allocated to the intervention group (one-phase oral contraceptive continuously during three subsequent months) or the reference group (three Leuprorelin 3.75 mg i.m./s.c. depot injections during three subsequent months). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Continuous oral contraceptives versus long-term pituitary desensitization prior to IVF/ICSI in moderate to severe endometriosis: study protocol of a non-inferiority randomized controlled trial
Herramientas de búsqueda: RSS